Skip to content
lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
May 31, 2026
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association’s 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
May 28, 2026
Foundayo and Zepbound now covered for millions of Americans
May 28, 2026
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
Lilly announces three acquisitions to build infectious disease portfolio
May 26, 2026
A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
May 25, 2026
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
May 22, 2026
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 21, 2026
Lilly to participate in Bernstein’s 42nd Annual Strategic Decisions Conference
May 18, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 16, 2026
1
2
3
…
6
Next Page
→